Skip to main
ABT

Abbott Labs (ABT) Stock Forecast & Price Target

Abbott Labs (ABT) Analyst Ratings

Based on 17 analyst ratings
Buy
Strong Buy 47%
Buy 41%
Hold 12%
Sell 0%
Strong Sell 0%

Bulls say

Abbott Laboratories continues to project a robust organic sales growth rate of 6.0-7.0% through 2025, with a consensus revenue expectation of approximately $44.69 billion, reflecting a year-over-year increase. Noteworthy performance in the company's Electrophysiology and Structural Heart sectors, including significant double-digit growth in key areas such as Diabetes and heart management devices, underlines Abbott's strong position in the medical device market. Furthermore, Abbott's commitment to increasing dividends for over 50 consecutive years, coupled with a strong balance sheet, suggests a stable financial foundation poised for potential mergers and acquisitions, reinforcing a positive outlook for the company's stock.

Bears say

Abbott Laboratories is facing significant challenges that contribute to a negative outlook on its stock, primarily due to a steep decline in Covid-19 testing-related sales, which fell from $265 million in Q3'24 to $69 million in Q3'25. Additionally, persistent macroeconomic pressures such as inflation and foreign exchange fluctuations are adversely affecting performance, alongside funding cuts for HIV testing that impact Abbott’s Rapid Diagnostics segment. The company's results were mixed, with a top-line miss driven by these factors, and concerns remain regarding the sustainability of its growth in core markets due to lagging expectations, particularly in China.

Abbott Labs (ABT) has been analyzed by 17 analysts, with a consensus rating of Buy. 47% of analysts recommend a Strong Buy, 41% recommend Buy, 12% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Abbott Labs and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Abbott Labs (ABT) Forecast

Analysts have given Abbott Labs (ABT) a Buy based on their latest research and market trends.

According to 17 analysts, Abbott Labs (ABT) has a Buy consensus rating as of Jan 9, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $146.94, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $146.94, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Abbott Labs (ABT)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.